<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445169</url>
  </required_header>
  <id_info>
    <org_study_id>6482-002</org_study_id>
    <secondary_id>PT2977-103</secondary_id>
    <nct_id>NCT03445169</nct_id>
  </id_info>
  <brief_title>A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, Food Effect Study in Healthy Volunteers With PT2977 Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peloton Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peloton Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1, single-dose study will be conducted in adult male and female subjects (N = 16)&#xD;
      who are in general good health and selected for participation in the study according to the&#xD;
      selection criteria. This study will assess the effect of food on the pharmacokinetics of&#xD;
      belzutifan Tablets. The study will consist of two periods and will be conducted in a&#xD;
      crossover fashion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized in equal numbers to two sequences of meal conditions (fasting and&#xD;
      non-fasting). Serial blood samples will be collected after dose administration in each&#xD;
      period. Subjects will be confined at the clinical research for a portion of each period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Actual">May 26, 2018</completion_date>
  <primary_completion_date type="Actual">May 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentrations of belzutifan assessed in both the fasting and non-fasting conditions and compared</measure>
    <time_frame>9 days in each of the fasting and non-fasting arms</time_frame>
    <description>Blood samples to assess concentrations of belzutifan will be collected throughout the sampling time frame</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belzutifan tablets taken after fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belzutifan taken after eating a high calorie meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belzutifan</intervention_name>
    <description>Belzutifan Tablets</description>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_label>Non-Fasting</arm_group_label>
    <other_name>MK-6482,</other_name>
    <other_name>PT2977</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or vasectomized male;&#xD;
&#xD;
          -  If of childbearing potential, willing to practice methods of birth control;&#xD;
&#xD;
          -  If of childbearing potential, must be non-pregnant and non-lactating and have a&#xD;
             negative serum pregnancy test result prior to enrollment into the trial;&#xD;
&#xD;
          -  Has a body mass index (BMI) between 19 and 32 kg/m2; Willing and able to give written&#xD;
             informed consent for study participation and provide consent for access to medical&#xD;
             data;&#xD;
&#xD;
          -  Willing and able to cooperate with all aspects of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any vaccination within 30 days before start of this study and throughout the study;&#xD;
&#xD;
          -  Abnormal blood pressure or pulse rate;&#xD;
&#xD;
          -  Abnormal screening electrocardiogram (ECG);&#xD;
&#xD;
          -  Receipt of any investigational agent within 30 days;&#xD;
&#xD;
          -  A positive history of drug abuse or a positive test result for drug(s) of abuse;&#xD;
&#xD;
          -  Female subjects who are planning a pregnancy or are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Spaulding Clinical</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

